Clinical Trials Logo

Clinical Trial Summary

The goal of this prospective, randomized, sham-controlled, crossover study is to evaluate the safety and feasibility of ExAblate Neuro treatment of chronic trigeminal neuropathic pain.


Clinical Trial Description

This study is to show that for patients with treatment-refractory chronic trigeminal neuropathic pain, ExAblate Neuro focused ultrasound (FUS) can safely create lesions bilaterally in the thalamic nuclei to reduce pain and provide functional benefits in daily activities. After informed consent and screening, eligible subjects will be randomized to either an ExAblate treatment or a Sham Control procedure. Subjects who are randomized to Sham Control will undergo the same procedure and follow-up visits through their Month 3 visit. After the Month 3 assessments are complete, all subjects will be un-blinded and those in the Sham treated group will have the option for an actual ExAblate treatment in an un-blinded fashion, as long as they still qualify for ExAblate treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03309813
Study type Interventional
Source InSightec
Contact
Status Active, not recruiting
Phase N/A
Start date December 1, 2017
Completion date October 2023

See also
  Status Clinical Trial Phase
Completed NCT03003715 - Brain as a Therapeutic and Research Target in Trigeminal Neuropathic Pain N/A
Terminated NCT02321566 - Motor Cortex Stimulation for the Treatment of Chronic Facial, Upper Extremity, and Throat Pain. Phase 1